Evidence map›Paper›PMID 41632395›Full record

ArticleBreast cancer (Tokyo, Japan)2026

Evaluating high-risk breast cancer surveillance outcomes in BRCA mutation carriers.

Yuk-Kwan Chang, Wing-Pan Luk, Ling-Hiu Fung, Ava Kwong

Abstract read
In one paragraph

Article in Breast cancer (Tokyo, Japan), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Yuk-Kwan ChangDepartment of Surgery, Queen Mary Hospital and Tung Wah Hospital, Hong Kong, Hong Kong S.A.R., China.
Wing-Pan LukResearch Department, Hong Kong Sanatorium and Hospital, Hong Kong, Hong Kong SAR, China.
Ling-Hiu FungResearch Department, Hong Kong Sanatorium and Hospital, Hong Kong, Hong Kong SAR, China.
Ava KwongDivision of Breast Surgery, Department of Surgery, School of Clinical Medicine, University of Hong Kong, Hong Kong Hereditary Breast Cancer Family Registry, Breast Surgery Centre and Cancer Genetics Centre, Hong Kong Sanatorium and Hospital, Hong Kong, Hong Kong SAR, China. avakwong@hku.hk.ORCID http://orcid.org/0000-0002-6968-9489

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundLong-term outcome on breast cancer surveillance in BRCA mutation carriers are limited, especially in Asian populations where uptake of preventive surgery is low.

methodsWe conducted a retrospective cohort study of 722 female BRCA1 and BRCA2 mutation carriers enrolled between January 2007 and December 2024 in the Hong Kong Hereditary Breast Cancer Family Registry. Of these, 702 (97.2%) underwent structured high-risk surveillance comprising biannual clinical breast examination and alternating 6-monthly breast magnetic resonance imaging and mammography or digital breast tomosynthesis with ultrasonography. The outcomes were breast cancer detection rate, stage, nodal status, interval cancer occurrence, and breast cancer–specific mortality.

resultsRisk-reducing mastectomy was undertaken by 90 out of 722 carriers (12.5%). Surveillance detected 64 breast cancers during 4,398 imaging sessions (detection rate 1.5%). Most cancers (89.1%) were diagnosed at stage 0 or I, and 95.3% were node- negative. Interval cancers were uncommon. Among 304 carriers initially free of breast cancer who later developed the disease (n = 26), no breast cancer–specific death occurred. Overall, breast cancer–specific mortality in the cohort was 2.4%, with most deaths due to ovarian cancer with a median follow-up of 39.1 months (range, 6-212.3). Longer term follow-up is warranted.

conclusionsIn this first Asian surveillance cohort of BRCA mutation carriers, prophylactic mastectomy uptake was low, yet structured screening enabled early-stage detection and minimal interval cancer. Surveillance should be considered as a key management strategy, with preventive surgery options individualized and cost-effectiveness evaluated.

Indexed as

BRCA1 ProteinBRCA2 ProteinBreast NeoplasmsEarly Detection of CancerAdultFemaleGenetic Predisposition to DiseaseHeterozygoteHong KongHumansMammographyMiddle AgedMutationProphylactic MastectomyRetrospective StudiesBRCA1 ProteinBRCA1 protein, humanBRCA2 ProteinBRCA2 protein, humanAsiaBRCA mutationHereditary breast cancerRisk-reducing mastectomySurveillance

Identifiers

PMID41632395
PMCPMC12960395

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.